Premium
Amyloid βprotein precursors with kunitz‐type inhibitor domains and acetyl‐cholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type
Author(s) -
Urakami K.,
Takahashi K.,
Saito H.,
Okada A.,
Nakamura S.,
Tanaka S.,
Kitaguchi N.,
Tokushima Y.,
Yamamoto S.
Publication year - 1992
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1992.tb04057.x
Subject(s) - acetylcholinesterase , cerebrospinal fluid , medicine , chemistry , endocrinology , cholinesterase , dementia , acetylcholine , amyloid (mycology) , acetylcholinesterase inhibitor , amyloid precursor protein , somatostatin , alzheimer's disease , biochemistry , enzyme , disease , inorganic chemistry
We used the ELISA to measure the concentration of amyloid protein precursor with Kunitz type trypsin inhibitor domains (APPI) in CSF of dementia of the Alzheimer type (DAT) and examined the correlation of APPI with acetylcholinesterase (AChE) and somatostatin (SRIF). We found the APPI concentration in CSF of DAT to be significantly elevated compared with that of multi‐infarct dementia and controls. We could significantly correlate APPI with AChE, but not correlate APPI with SRIF. The present results suggest that measurement of CSF APPI levels may be useful for diagnosis of DAT and the change of APPI may closely be associated with abnormality of acetylcholine system in DAT that has been reported.